Article

Experimental medical mycological research in Latin America - a 2000-2009 overview

Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela.
Revista iberoamericana de micología 12/2010; 28(1):1-25. DOI: 10.1016/j.riam.2010.11.004
Source: PubMed

ABSTRACT Se presenta una revisión de lasmásimportantes líneas de investigación en micología médica experimental en América Latina desde el inicio del siglo XXI (búsqueda bibliográfica desde enero de 2000 a diciembre de 2009). Usando las bases de datos PubMed y LILACS, los autores hemos escogido publicaciones en hongos patógenos de importancia clínica que, de acuerdo a nuestra opinión, son las más relevantes por su novedad, interés e impacto internacional, basadas en investigaciones realizadas totalmente en la región latinoamericana o como parte de esfuerzos colaborativos con laboratorios de otras partes del mundo.
De esta forma, discutimos las siguientes áreas: 1) identificación molecular de patógenos fúngicos; 2) epidemiología clínica y molecular de hongos patógenos prevalentes en la región; 3) biología celular; 4) transcriptoma, genoma, taxonomía y filogenia moleculares; 5) inmunología; 6) vacunas; 7) antifúngicos nuevos o experimentales.

Download full-text

Full-text

Available from: Eva Burger, Jul 16, 2015
0 Followers
 · 
282 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: La caspofungine est une échinocandine prescrite pour le traitement des infections fongiques invasives causées par Candida sp. et Aspergillus sp. Le but de cette étude est d’évaluer le degré de sensibilité à la caspofungine de Candida sp., isolé à partir d’hémocultures dans l’état du Ceará (Brésil) par la méthode de microdilution. Trente-trois souches de Candida sp. ont été sélectionnées pour le test (sept C. albicans, neuf C. tropicalis et 17 C. parapsilosis) ; ces souches sont le plus souvent isolées dans des infections fongiques en Ceará. Les résultats des tests de sensibilité par microdilution peuvent être lus à 24 ou 48 heures après les tests, sans compromettre les interprétations du test. C. parapsilosis montre les CMI les plus élevées comparativement à celles de C. albicans et C. tropicalis pour la caspofungine.
    Journal de Mycologie Médicale/Journal of Medical Mycology 12/2011; 21(4). DOI:10.1016/j.mycmed.2011.09.006 · 0.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pathogenic role of invasive fungal infections (IFIs) has increased during the past two decades in Latin America and worldwide, and the number of patients at risk has risen dramatically. Working habits and leisure activities have also been a focus of attention by public health officials, as endemic mycoses have provoked a number of outbreaks. An extensive search of medical literature from Latin America suggests that the incidence of IFIs from both endemic and opportunistic fungi has increased. The increase in endemic mycoses is probably related to population changes (migration, tourism, and increased population growth), whereas the increase in opportunistic mycoses may be associated with the greater number of people at risk. In both cases, the early and appropriate use of diagnostic procedures has improved diagnosis and outcome.
    Current Fungal Infection Reports 03/2012; 6(1):23-34. DOI:10.1007/s12281-011-0081-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microparticles (MPs) and nanoparticles (NPs) have received considerable attention for the design of drug delivery systems (DDS) with unique properties owing to the increased surface area and the ability to fine tune the release process. More recently, a new type of DDS that capitalize on the advantages of both NPs and MPs has been introduced. Nanoparticle-in-Microparticle Delivery Systems (NiMDS) comprise the encapsulation of NPs within MPs and lead to features that are unique and different from those of the individual components. These technology platforms can be produced employing from conventional to more sophisticated methodologies and equipment and they are administered by different routes such as oral, pulmonary or even parenteral. Moreover, if designed appropriately, “they can (i) protect drug payloads and prevent physical and chemical instability phenomena in the biological environment, (ii) improve the release profile of the encapsulated agent, (iii) reduce or eliminate the burst effect and (iv) target specific cells, tissues and organs.” Should be changed to “they can protect drug payloads and prevent physical and chemical instability phenomena in the biological environment, improve the release profile of the encapsulated agent, reduce or eliminate the burst effect and target specific cells, tissues and organs.”
    02/2013; 3(1):22-38. DOI:10.1166/jbt.2013.1064
Show more